ArticleEcancermedicalscience2019

Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status.

Ali Calderon-Aparicio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.